SynthesisPsychiatric genetics2008
PDLIM5 and susceptibility to bipolar disorder: a family-based association study and meta-analysis.
Synthesis in Psychiatric genetics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- High-resolution chromosome ideogram representation of recognized genes for bipolar disorder.Gene · 2016Article
- Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models.Frontiers in psychiatry · 2015Review
- Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice.PloS one · 2013Article
- Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration.BMC medical genetics · 2012Article
- Meta-analysis of haplotype-association studies: comparison of methods and empirical evaluation of the literature.BMC genetics · 2011Article
- Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome.Brain research bulletin · 2010Review
- The PCSK9 Protein Is Not Necessarily a Risk Factor for Major Depressive Disorder.Basic and clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe postsynaptic density-95/discs large/zone occludens-1 (PDZ) domain and LIM (Lin-11, Isl-1, and Mec-3) domain 5 (PDLIM5) gene has been analyzed as a candidate gene for both schizophrenia and bipolar disorder (BP) in Japanese samples. We performed a family-based association study to test the hypothesis that variants in PDLIM5 increase susceptibility to BP in European-Americans and a meta-analysis to clarify whether there is a single marker consistently contributing to risk for BP.
methodsFive single nucleotide polymorphisms in the PDLIM5 gene were genotyped in 290 European-American BP families. Programs Sibling-Transmission/Disequilibrium Test (sib_tdt) and PDTPHASE were used for allelic and haplotypic association, respectively. We carried out a meta-analysis combing our family-based data and case-control data from two Japanese sample sets and from two genome-wide association (GWA) studies.
resultsOur association analysis showed no single nucleotide polymorphism associated with BP. A rare haplotype consisted of rs10008257 and rs2433320 had nominal association (P=0.045), which failed to survive correction for multiple tests. The meta-analysis identified a significant allelic association at rs2433320 in all combined samples (excluding overlapped samples in GWA: overall odds ratio=0.897, 95% confidence interval: 0.838-0.961, adjusted P=0.012) and in all Caucasian samples (excluding overlapped samples in GWA: overall odds ratio=0.905, 95% confidence interval: 0.843-0.971, adjusted P=0.032), but not in the Japanese samples.
conclusionPDLIM5 may have a minor effect on susceptibility to BP in Caucasians. The findings in Japanese need further confirmation in larger independent samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.